Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
Oliva S, De Paoli L, Ruggeri M, Caltagirone S, Troia R, Oddolo D, D'Agostino M, Gilestro M, Mina R, Saraci E, Margiotta Casaluci G, Genuardi E, Bringhen S, Boccadoro M, Omedé P. Oliva S, et al. Among authors: troia r. Ann Hematol. 2021 Feb;100(2):437-443. doi: 10.1007/s00277-020-04384-w. Epub 2021 Jan 3. Ann Hematol. 2021. PMID: 33392702
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.
Gay F, Mina R, Troia R, Bringhen S. Gay F, et al. Among authors: troia r. Expert Opin Drug Metab Toxicol. 2013 Nov;9(11):1517-27. doi: 10.1517/17425255.2013.827169. Epub 2013 Aug 21. Expert Opin Drug Metab Toxicol. 2013. PMID: 23961770 Free article. Review.
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.
Bringhen S, Mina R, Cafro AM, Liberati AM, Spada S, Belotti A, Gaidano G, Patriarca F, Troia R, Fanin R, De Paoli L, Rossi G, Lombardo A, Bertazzoni P, Palumbo A, Sonneveld P, Boccadoro M. Bringhen S, et al. Among authors: troia r. Leukemia. 2018 Aug;32(8):1803-1807. doi: 10.1038/s41375-018-0024-1. Epub 2018 Jan 30. Leukemia. 2018. PMID: 29479061 Free article. Clinical Trial. No abstract available.
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M, Omedé P, Spada S, Muccio VE, Gilestro M, Saraci E, Grammatico S, Larocca A, Conticello C, Bernardini A, Gamberi B, Troia R, Liberati AM, Offidani M, Rocci A, Palumbo A, Cavo M, Sonneveld P, Boccadoro M, Oliva S. Gambella M, et al. Among authors: troia r. Cancer. 2019 Mar 1;125(5):750-760. doi: 10.1002/cncr.31854. Epub 2018 Dec 18. Cancer. 2019. PMID: 30561775 Free article.
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.
Oliva S, Bruinink DHO, Rihova L, D'Agostino M, Pantani L, Capra A, van der Holt B, Troia R, Petrucci MT, Villanova T, Vsianska P, Jugooa R, Brandt-Hagens C, Gilestro M, Offidani M, Ribolla R, Galli M, Hajek R, Gay F, Cavo M, Omedé P, van der Velden VHJ, Boccadoro M, Sonneveld P. Oliva S, et al. Among authors: troia r. Blood Cancer J. 2021 Jun 3;11(6):106. doi: 10.1038/s41408-021-00498-0. Blood Cancer J. 2021. PMID: 34083504 Free PMC article. Clinical Trial.
Melphalan hydrochloride for the treatment of multiple myeloma.
Esma F, Salvini M, Troia R, Boccadoro M, Larocca A, Pautasso C. Esma F, et al. Among authors: troia r. Expert Opin Pharmacother. 2017 Aug;18(11):1127-1136. doi: 10.1080/14656566.2017.1349102. Epub 2017 Jul 10. Expert Opin Pharmacother. 2017. PMID: 28658983 Free article. Review.
54 results